| Literature DB >> 22970347 |
Moses N Katabarwa1, Frank Walsh, Peace Habomugisha, Thomson L Lakwo, Stella Agunyo, David W Oguttu, Thomas R Unnasch, Dickson Unoba, Edson Byamukama, Ephraim Tukesiga, Richard Ndyomugyenyi, Frank O Richards.
Abstract
Wadelai, an isolated focus for onchocerciasis in northwest Uganda, was selected for piloting an onchocerciasis elimination strategy that was ultimately the precursor for countrywide onchocerciasis elimination policy. The Wadelai focus strategy was to increase ivermectin treatments from annual to semiannual frequency and expand geographic area in order to include communities with nodule rate of less than 20%. These communities had not been covered by the previous policy that sought to control onchocerciasis only as a public health problem. From 2006 to 2010, Wadelai program successfully attained ultimate treatment goal (UTG), treatment coverage of ≥90%, despite expanding from 19 to 34 communities and from 5,600 annual treatments to over 29,000 semiannual treatments. Evaluations in 2009 showed no microfilaria in skin snips of over 500 persons examined, and only 1 of 3011 children was IgG4 antibody positive to the OV16 recombinant antigen. No Simulium vectors were found, and their disappearance could have sped up interruption of transmission. Although twice-per-year treatment had an unclear role in interruption of transmission, the experience demonstrated that twice-per-year treatment is feasible in the Ugandan setting. The monitoring data support the conclusion that onchocerciasis has been eliminated from the Wadelai focus of Uganda.Entities:
Year: 2012 PMID: 22970347 PMCID: PMC3433138 DOI: 10.1155/2012/748540
Source DB: PubMed Journal: J Parasitol Res ISSN: 2090-0023
Figure 1Wadelai focus 1993 rapid epidemiological assessment (REA) map of onchocerciaisis by nodule prevalence.
Figure 2History of mass treatment with ivermectin from 1993 to 2010 in Wadelai onchocerciasis focus, Uganda.
Figure 3History of percent treatment coverage with ivermectin annually 1993 to 2005 (UTG), and twice yearly (UTG2) from 2006–2010 in Wadelai onchocerciasis focus, Uganda.
Prevalence of skin snips (microscopy) and nodules in 2009.
| Community | No. examined | % mf | % nodule |
|---|---|---|---|
| prevalence | prevalence∗∗ | ||
| Aguu West | 88 | 0 | 2.3 |
| Olimbuni/Aroga∗ | 75 | 0 | 0 |
| Aroga Leba | 70 | 0 | 0 |
| Lwalo | 120 | 0 | 2.5 |
| Ojigo East | 108 | 0 | 1.9 |
| Pailo East | 52 | 0 | 0 |
|
| |||
| Total | 513 | 0 | 1.12 |
∗Baseline parasitological assessments (Aroga sentinel community) in 1993-mf % positive = 24% of 50 adults and nodule prevalence = 50% of 30 adults.
∗∗Only one of six nodules was parasitologically confirmed. The confirmed nodule did not contain any viable adult worms.
Blood spots from children ≤14 years of age (n = 3011) from Wadelai onchocerciasis focus tested for IgG4 antibodies against the OV-16 recombinant antigen in 2009.
| Age group | No. screened | No. positive | % positive |
|---|---|---|---|
| 1 to 4 | 1080 | 0 | 0 |
| 5 to 9 | 1058 | 0 | 0.19 |
| 10 to ≤14 | 873 | 1 | 0.11 |
|
| |||
| Total | 3011 | 1 | 0.03 |
NB: Only the putative positive individual in age group 10 to ≤14 years was PCR positive by O-150 skin snip PCR, indicating patent infection.